TLR9 and neoplasm: To assess whether STAT3 activation restrained the TLR4/TLR9 agonist complex-induced STAT1 activation and autophagy-associated tumor cell death, AG490, a selective JAK/STAT inhibitor, was administered with or without the complex after tumor inoculation.